We are giving life to new classes of medicine to change the lives of patients with devastating diseases
We are giving life to new classes of medicine to change the lives of patients with devastating diseases
Strong track record of clinical success, outperforming the biopharma industry average by 6x1
0
New therapeutics and therapeutic candidates generated from PureTech's R&D engine
0
Are clinical indications being pursued by PureTech or its Founded Entities
0
Soon to be filed for FDA approval
0
Taken from inception at PureTech to FDA and EU regulatory clearances
Unlocking the Potential of Validated Efficacy
We do this by enhancing on-target efficacy, enabling oral administration or improving tolerability to unlock new classes of medicine
Seasoned Senior Leadership
Our team oversaw R&D of therapeutics supporting 27 regulatory approvals and served in the C-suite of companies acquired for more than $14B in aggregate
Our network of scientific collaborators enables us to identify or co-invent key intellectual property before it's published in major journals
Our network of scientific collaborators enables us to identify or co-invent key intellectual property before it's published in major journals
News & Press
Clinical success is measured as the probability of transition success from Phase 1 to regulatory filing. PureTech’s probability is 47%, and the industry average is 8%. The cumulative percentages are calculated by multiplying the individual phase percentages. Industry average data measures the probability of clinical trial success of therapeutics by calculating the number of programs progressing to the next phase vs. the number progressing and suspended (Phase 1=52%, Phase 2=29%, Phase 3=58%). BIO, PharmaIntelligence, QLS (2021) Clinical Development Success Rates 2011 – 2020. This report did not include therapeutics regulated as devices. PureTech average data measures aggregate percentages including all therapeutic candidates advanced through at least Phase 1 by PureTech or its Founded Entities from 2009 onward, using the aforementioned calculation method based on the following individual phase percentages, Phase 1 (n = 6/8; 75%), Phase 2 (n = 10/12; 83%), Phase 3 (n = 3/4; 75%), last updated on August 8, 2022; Phase 2 and Phase 3 percentages include some therapeutic candidates where Phase 1 trials were not conducted by PureTech or its Founded Entities (i) due to the requirements of the medical device regulatory pathway or (ii) because a prior Phase 1 trial was conducted by a third party, which Phase 1 trials were not included in this analysis.